DCD受者肾移植术后白细胞减少发生情况分析

doi:10.3969/j.issn.1671-7171.2018.06.023

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the incidence of leukopenia in DCD (organ donation after cardiac death) recipients after renal transplantation. 【Methods】We retrospectively analyzed the clinical data of 83 DCD recipients from January 2012 to January 2017 who underwent renal transplantation in our hospital. According to whether or not ganciclovir was administered, patients were divided into the observation group (immunosuppressive agents + ganciclovir,n=62) and the control group (immunosuppressive group only,n=21). The occurrences of leukopenia in both groups were statistically analyzed. 【Results】In the observation group, leukopenia occurred in 22 cases (35.48%), including a mild 10 cases (16.13%), a moderate 6 cases (9.68%), a severe 4 cases (6.45%), and a critical 2 cases (3.23%). In the control group, neutropenia occurred in 3 patients (14.29%), including 1 mild case (4.76%), 1 moderate case (4.76%), 1 severe case (4.76%), and 0 critical cases. The incidence of leukopenia in the control group was significantly lower than that in the observation group (χ²=5.152,P=0.015<0.05). Except for one case of critical leukopenia with death, the white blood cells in all other cases returned to normal after treatment. 【Conclusion】The reduction of leukopenia after renal transplantation in DCD recipients is common, and the combined use of immunosuppressants with antiviral drugs is one of the common causes. Most patients can recover to normal levels after symptomatic treatment.

Key words： TissueDonors KidneyTransplantation Leukopenia

Received: 25 August 2017

PACS:

R699.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIANG Fang-fang
	ZHAGN Jian-qiang
	HUAGN Fu
	et al

Cite this article:

LIANG Fang-fang,ZHAGN Jian-qiang,HUAGN Fu, et al. Analysis of Leukopenia in DCD Recipients after Renal Transplantation[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(6): 1110-1112.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.06.023 OR http://www.jcr.net.cn/EN/Y2018/V35/I6/1110

[1] 刘斌, 曾凡军, 陈知水, 等. 心脏死亡器官捐献供者肾移植的近期效果评价[J].第三军医大学学报, 2015, 37(1): 64-68.
[2] 闫巍, 韩修武, 邢晓燕,等.肾移植术后吗替麦考酚酯和硫唑嘌呤导致白细胞减少症的临床分析[J].河北医药, 2010, 32(7):784-786.
[3] Saliba F, Rostaing L, Gugenheim J,et al.Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: A randomized, multicenter study[J].Transplant,2016, 100(8): 1705-1713.
[4] 龚朝阳, 邓德成, 侯敬财,等. 心脏死亡捐献供肾肾移植术后白细胞减少的临床分析[J].深圳中西医结合杂志, 2015, 25(11):78-79.
[5] 肖海静. 肾移植后不同免疫抑制剂抗排斥反应的临床应用及不良反应[J].中国组织工程研究, 2012, 16(18): 3383-3386.
[6] 常征, 郝俊文, 张爱民. ATG-F 与 OKT3 在肾移植术后急性排斥反应中的应用效果[J].实用医药杂志, 2016, 33(8): 695-698.
[7] Cuervas Mons V, Herrero JI, Gomez MA,et al. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients[J].Clin Transplant,2015, 29(8): 667-677.
[8] 许圣淳, 刘正钊, 章海涛, 等. 吗替麦考酚酯诱导治疗弥漫增生性狼疮性肾炎的临床疗效[J]. 肾脏病与透析肾移植杂志, 2014, 23(6):1-6.
[9] Bejanyan N, Rogosheske J, DeFor T, et al. Higher dose of mycophenolate mofetil reduces acute graft-versus-host disease in reduced-intensity conditioning double umbilical cord blood transplantation[J].Biol Blood Marrow Transplant,2015, 21(5): 926-933.
[10] 王岩. 吗替麦考酚酯对弥漫增生性狼疮性肾炎的诱导治疗疗效[J].中国卫生标准管理, 2015,16(29): 109-110.
[11] Harnicar S, Ponce DM, Hilden P, et al. Intensified mycophenolate mofetil dosing and higher mycophenolic acid trough levels reduce severe acute graft-versus-host disease after double-unit cord blood transplantation[J].Biol Blood Marrow Transplant,2015, 21(5): 920-925.
[12] 李琳霞. 缬沙坦联合泼尼松, 吗替麦考酚酯治疗小儿难治性肾病综合征的近期疗效观察[J].中国医学创新, 2015, 12(02): 19-21.
[13] 季曙明, 陈江华, 谭建明, 等. 肾移植后吗替麦考酚酯联合低剂量他克莫司加皮质激素的应用[J].中国组织工程研究, 2013, 17(5): 777-784.
[14] Al Maimouni H, Gladman DD, Iba ez D, et al. Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes[J].Arthritis Care Res,2014, 66(12): 1905-1909.
[15] Nambiar AM, Anzueto AR, Peters JI. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis[J].PLoS One,2017, 12(4): e0176312.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(9): 1856-1858.